MedTrace Logo

Open, Non-comparative Pilot Study to Evaluate the Safety and Efficacy of Intraovarian Plasma Rich in Growth Factors (PRGF) in Patients With Low Ovarian Reserve

NCT06975683 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-06-12

No results posted yet for this study

Summary

The use of plasma rich in growth factors (PRGF) improves ovarian reserve markers and IVF laboratory parameters in women with low ovarian reserve.

Primary objective To compare ovarian reserve markers and IVF-ICSI laboratory results before and after PRGF infusion.

Secondary Objectives

* To compare pre- and post-treatment pregnancy rates.
* To collect complications associated with the application of intraovarian PRGF. General Outline of the Study VISIT 1
* Patient Selection
* Confirm that he/she has all the analyses and variables to be studied.
* Signing of Informed Consent
* Usual IVF protocol (1st IVF cycle) VISIT 2
* Instillation of intraovarian PRGF on the day of the puncture of the 1st IVF cycle in the FJD VISIT 3
* Analytical control at 4 weeks VISIT 4
* Analytical control at 8 weeks VISIT 5
* In case of failure to achieve gestation Start of 2nd cycle of IVF

Conditions

  • Low Ovarian Reserve

Interventions

BIOLOGICAL

Plasma Rich in Growth Factors (PRGF)

On the day of the ovarian puncture of the 1st IVF cycle, intraovarian instillation of plasma rich in growth factors will be performed.

Sponsors & Collaborators

  • Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-30
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06975683 on ClinicalTrials.gov